https://www.biospace.com/american-society-of-clinical-oncology-asco ASCO en-US Mon, 08 Jun 2026 01:32:52 GMT https://www.biospace.com/press-releases/diakonos-oncology-shares-updated-doc1021-gbm-survival-data-and-unveils-melanoma-clinical-study-at-asco-2026 Mon, 08 Jun 2026 01:32:52 GMT https://www.biospace.com/press-releases/diakonos-oncology-shares-updated-doc1021-gbm-survival-data-and-unveils-melanoma-clinical-study-at-asco-2026 https://www.biospace.com/press-releases/akari-therapeutics-releases-ceo-corner-reflecting-on-evolving-adc-landscape-and-akaris-differentiated-ph1-payload-platform-following-asco-2026 Fri, 05 Jun 2026 02:13:18 GMT https://www.biospace.com/press-releases/akari-therapeutics-releases-ceo-corner-reflecting-on-evolving-adc-landscape-and-akaris-differentiated-ph1-payload-platform-following-asco-2026 https://www.biospace.com/press-releases/nxtc-announces-replay-available-for-virtual-kol-event-discussing-asco-2026-dose-escalation-data-from-phase-1-trial-of-sim0505-for-gynecologic-cancers Thu, 04 Jun 2026 12:55:57 GMT https://www.biospace.com/press-releases/nxtc-announces-replay-available-for-virtual-kol-event-discussing-asco-2026-dose-escalation-data-from-phase-1-trial-of-sim0505-for-gynecologic-cancers https://www.biospace.com/press-releases/medicennas-mdna11-potential-in-earlier-line-melanoma-setting-highlighted-in-presentation-of-the-neo-cyt-trial-at-asco-2026 Wed, 03 Jun 2026 12:06:36 GMT https://www.biospace.com/press-releases/medicennas-mdna11-potential-in-earlier-line-melanoma-setting-highlighted-in-presentation-of-the-neo-cyt-trial-at-asco-2026 https://www.biospace.com/press-releases/asco-2026-updated-data-from-an-oral-presentation-of-innocares-novel-bcl2-inhibitor-mesutoclax-in-mds-and-aml-released Wed, 03 Jun 2026 07:33:29 GMT https://www.biospace.com/press-releases/asco-2026-updated-data-from-an-oral-presentation-of-innocares-novel-bcl2-inhibitor-mesutoclax-in-mds-and-aml-released https://www.biospace.com/press-releases/kelun-biotech-presents-first-in-human-study-data-for-its-novel-b7-h3-adc-skb500-at-asco-2026 Wed, 03 Jun 2026 07:32:35 GMT https://www.biospace.com/press-releases/kelun-biotech-presents-first-in-human-study-data-for-its-novel-b7-h3-adc-skb500-at-asco-2026 https://www.biospace.com/press-releases/syndax-highlights-revuforj-revumenib-data-presented-at-asco-2026-including-an-oral-presentation-of-post-transplant-data Wed, 03 Jun 2026 07:03:13 GMT https://www.biospace.com/press-releases/syndax-highlights-revuforj-revumenib-data-presented-at-asco-2026-including-an-oral-presentation-of-post-transplant-data https://www.biospace.com/press-releases/stelexis-biosciences-announces-positive-phase-1-data-for-eganelisib-in-relapsed-refractory-aml-and-higher-risk-mds-in-an-oral-presentation-at-asco-2026 Wed, 03 Jun 2026 05:54:58 GMT https://www.biospace.com/press-releases/stelexis-biosciences-announces-positive-phase-1-data-for-eganelisib-in-relapsed-refractory-aml-and-higher-risk-mds-in-an-oral-presentation-at-asco-2026 https://www.biospace.com/press-releases/cardiff-oncology-announces-presentation-of-positive-results-from-its-randomized-controlled-phase-2-trial-of-onvansertib-in-first-line-ras-mutated-mcrc-at-the-2026-asco-annual-meeting Wed, 03 Jun 2026 01:37:34 GMT https://www.biospace.com/press-releases/cardiff-oncology-announces-presentation-of-positive-results-from-its-randomized-controlled-phase-2-trial-of-onvansertib-in-first-line-ras-mutated-mcrc-at-the-2026-asco-annual-meeting https://www.biospace.com/press-releases/disc-medicine-presents-updated-positive-data-from-rally-mf-phase-2-trial-in-patients-with-myelofibrosis-mf-and-anemia-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting Tue, 02 Jun 2026 13:27:44 GMT https://www.biospace.com/press-releases/disc-medicine-presents-updated-positive-data-from-rally-mf-phase-2-trial-in-patients-with-myelofibrosis-mf-and-anemia-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting https://www.biospace.com/press-releases/seed-therapeutics-highlights-clinical-advancement-and-broad-oncology-potential-of-st-01156-an-rbm39-molecular-glue-degrader-in-first-in-human-in-phase-1-studies-at-asco-2026 Tue, 02 Jun 2026 12:38:41 GMT https://www.biospace.com/press-releases/seed-therapeutics-highlights-clinical-advancement-and-broad-oncology-potential-of-st-01156-an-rbm39-molecular-glue-degrader-in-first-in-human-in-phase-1-studies-at-asco-2026 https://www.biospace.com/press-releases/beyondspring-presents-the-latest-update-of-a-phase-2-study-demonstrating-durable-clinical-benefit-of-pembrolizumab-plus-plinabulin-docetaxel-in-metastatic-nsclc-after-progression-on-first-line-immune-checkpoint-inhibitor-therapy-at-asco-2026 Tue, 02 Jun 2026 12:35:58 GMT https://www.biospace.com/press-releases/beyondspring-presents-the-latest-update-of-a-phase-2-study-demonstrating-durable-clinical-benefit-of-pembrolizumab-plus-plinabulin-docetaxel-in-metastatic-nsclc-after-progression-on-first-line-immune-checkpoint-inhibitor-therapy-at-asco-2026 https://www.biospace.com/press-releases/personalis-highlights-early-colorectal-cancer-recurrence-detection-and-ultrasensitive-mrd-performance-across-a-broad-set-of-tumor-types-at-asco-2026 Tue, 02 Jun 2026 11:07:15 GMT https://www.biospace.com/press-releases/personalis-highlights-early-colorectal-cancer-recurrence-detection-and-ultrasensitive-mrd-performance-across-a-broad-set-of-tumor-types-at-asco-2026 https://www.biospace.com/press-releases/fulgent-presents-updated-fid-007-data-at-asco-2026 Tue, 02 Jun 2026 06:54:36 GMT https://www.biospace.com/press-releases/fulgent-presents-updated-fid-007-data-at-asco-2026 https://www.biospace.com/press-releases/ono-pharma-announces-oral-presentation-of-new-data-from-the-phase-2-clinical-study-of-ono-4578-ep4-antagonist-in-certain-gastric-cancers-at-the-asco-2026-annual-meeting Tue, 02 Jun 2026 06:54:24 GMT https://www.biospace.com/press-releases/ono-pharma-announces-oral-presentation-of-new-data-from-the-phase-2-clinical-study-of-ono-4578-ep4-antagonist-in-certain-gastric-cancers-at-the-asco-2026-annual-meeting https://www.biospace.com/press-releases/prostact-global-phase-3-part-1-data-presented-in-late-breaking-oral-session-at-asco-2026 Tue, 02 Jun 2026 06:51:13 GMT https://www.biospace.com/press-releases/prostact-global-phase-3-part-1-data-presented-in-late-breaking-oral-session-at-asco-2026 https://www.biospace.com/press-releases/immunitybio-presents-new-clinical-and-comparative-data-across-lung-and-bladder-cancer-at-asco-2026 Tue, 02 Jun 2026 06:47:00 GMT https://www.biospace.com/press-releases/immunitybio-presents-new-clinical-and-comparative-data-across-lung-and-bladder-cancer-at-asco-2026 https://www.biospace.com/press-releases/sumitomo-pharma-america-presents-first-clinical-data-for-smp-3124lp-an-investigational-pegylated-liposome-chk1-inhibitor-at-asco-2026 Tue, 02 Jun 2026 04:06:50 GMT https://www.biospace.com/press-releases/sumitomo-pharma-america-presents-first-clinical-data-for-smp-3124lp-an-investigational-pegylated-liposome-chk1-inhibitor-at-asco-2026 https://www.biospace.com/press-releases/legend-biotech-presents-first-in-human-lb2102-results-in-solid-tumors-and-new-carvykti-data-in-multiple-myeloma-at-asco-2026 Tue, 02 Jun 2026 03:50:10 GMT https://www.biospace.com/press-releases/legend-biotech-presents-first-in-human-lb2102-results-in-solid-tumors-and-new-carvykti-data-in-multiple-myeloma-at-asco-2026 https://www.biospace.com/press-releases/paradigm-health-implements-new-clinical-trial-solution-to-support-observational-study-presented-at-asco Tue, 02 Jun 2026 03:44:39 GMT https://www.biospace.com/press-releases/paradigm-health-implements-new-clinical-trial-solution-to-support-observational-study-presented-at-asco